• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Nat Commun . Whole-protein screening and multi-modal profiling of antigen-specific CD4+ T cells at single-cell resolution

tetano

Editor, Senior Moderator
Nat Commun


. 2026 May 12;17(1):3979.
doi: 10.1038/s41467-026-72396-7.
Whole-protein screening and multi-modal profiling of antigen-specific CD4[SUP]+[/SUP] T cells at single-cell resolution

Rongyu Zhang[SUP] 1 2 [/SUP], Jingqi Qi[SUP] 1 2 [/SUP], Michaela McKasson[SUP] 1 [/SUP], Jongchan Choi[SUP] 1 [/SUP], Vanessa Gutierrez[SUP] 1 [/SUP], Conor Brennan[SUP] 1 [/SUP], Sunga Hong[SUP] 1 [/SUP], William Chour[SUP] 1 3 [/SUP], Rachel H Ng[SUP] 1 2 [/SUP], Jingyi Xie[SUP] 1 4 [/SUP], Dan Yuan[SUP] 1 2 [/SUP], Andrew Webster[SUP] 1 [/SUP], Simranjeet K Sidhu[SUP] 1 2 [/SUP], Abby Anderson[SUP] 1 2 [/SUP], Daniel Chen[SUP] 1 [/SUP], Rick Edmark[SUP] 1 [/SUP], Kim M Murray[SUP] 1 [/SUP], Sarah Li[SUP] 1 [/SUP], Connor McDonald[SUP] 1 [/SUP], Lee Rowen[SUP] 1 [/SUP], Shuo Wang[SUP] 1 2 [/SUP], Yusuf Rasheed[SUP] 1 [/SUP], Yapeng Su[SUP] 1 5 [/SUP], Jamie R Wagner[SUP] 6 [/SUP], Jia Ming Chen[SUP] 7 [/SUP], Karla Nawaly[SUP] 7 [/SUP], Jie Fu[SUP] 8 [/SUP], Alexandria Duven[SUP] 9 [/SUP], Stephen J Forman[SUP] 6 [/SUP], Mihae Song[SUP] 10 [/SUP], Saul J Priceman[SUP] 11 [/SUP], Christine E Brown[SUP] 6 [/SUP], Antoni Ribas[SUP] 7 [/SUP], Deborah J Wong[SUP] 7 [/SUP], Kelly G Paulson[SUP] 12 13 [/SUP], Charles W Drescher[SUP] 5 12 [/SUP], Cristina Puig-Saus[SUP] 7 [/SUP], Jason D Goldman[SUP] 9 14 15 [/SUP], Cornelia L Trimble[SUP] 8 [/SUP], James R Heath[SUP] 16 17 18 [/SUP]


Affiliations
Abstract

Systematic whole-protein screening and comprehensive profiling of antigen-specific CD4[SUP]+[/SUP] T cells are crucial for advancing vaccine design and cancer immunotherapies, yet remain technically challenging. Here, we present a high-throughput platform that utilizes large-scale class II single-chain trimer libraries to detect antigen-specific CD4[SUP]+[/SUP] T cells, while simultaneously profiling their antigen specificity, TCRα/β sequences, MHC restriction, whole transcriptomes, and patient/timepoint origins at single-cell resolution. Upon rigorous platform validation, we screened the full SARS-CoV-2 spike receptor binding domain in a longitudinal cohort of 22 participants, identifying 2,188 antigen-specific CD4[SUP]+[/SUP] T cells and showing key metrics defining the immunogenicity of class II-restricted viral antigens. We further extended the platform to whole-protein screening of HPV-16 E6/E7 in a cohort of precancerous patients, indicating HPV-specific CD4 TCRs that, upon extensive characterization, demonstrate strong therapeutic potential. By integrating high-throughput antigen screening with high-dimensional, multi-modal cellular characterization, our approach provides detailed insight into CD4[SUP]+[/SUP] T cell immunity, potentially guiding vaccine design and next-generation TCR-based cancer immunotherapies.


 
Back
Top